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Oesophageal carcinoma
Arjun Pennathur, Michael K Gibson, Blair A Jobe, James D Luketich
Oesophageal carcinoma aﬀ ects more than 450 000 people worldwide and the incidence is rapidly increasing. Squamous-
cell carcinoma is the predominant form of oesophageal carcinoma worldwide, but a shift in epidemiology has been seen 
in Australia, the UK, the USA, and some western European countries (eg, Finland, France, and the Netherlands), where 
the incidence of adenocarcinoma now exceeds that of squamous-cell types. The overall 5-year survival of patients with 
oesophageal carcinoma ranges from 15% to 25%. Diagnoses made at earlier stages are associated with better outcomes 
than those made at later stages. In this Seminar we discuss the epidemiology, pathophysiology, diagnosis and staging, 
management, prevention, and advances in the treatment of oesophageal carcinoma.
Introduction
Oesophageal carcinoma is the sixth leading cause of 
cancer-related mortality and the eighth most common 
cancer worldwide. It aﬀ ects more than 450 000 people 
worldwide and the incidence is increasing rapidly.1–5 The 
overall 5-year survival ranges from 15% to 25%, and the 
best outcomes are associated with disease diagnosed in 
the early stages.3,6 Poor outcomes in patients with 
oesophageal cancer are related to diagnosis at advanced 
(metastatic) stages and the propensity for metastases, 
even when tumours are superﬁ cial.6 Although treatment 
of oesophageal carcinoma remains challenging, treat-
ment is best approached by a multidis ciplinary team and 
advances are resulting in progress.7,8 In this Seminar we 
review the epidemiology, patho physiology, diagnosis and 
staging, management, and prevention of oesophageal 
carcinoma, and discuss advances in treatment.
Epidemiology
Squamous-cell carcinoma (SCC) is the predominant 
histological type of oesophageal carcinoma worldwide. In 
Australia, the UK, the USA, and some western European 
countries (eg, Finland, France, and the Netherlands), 
however, the incidence of oesophageal adenocarcinoma 
now exceeds that of SCC (appendix p 1–2).4,5 Other less 
common types of oesophageal carcinoma include mela-
noma, leiomyo sarcoma, and small-cell carcinoma.3
The incidence of oesophageal carcinoma varies widely 
by region.9 The so-called Asian belt, which encompasses 
Turkey, northeastern Iran, Kazakhstan, and northern and 
central China (appendix p 3), has a very high incidence of 
oesophageal SCC, with more than 100 cases per 
100 000 population annually. Distribution is equal in 
men and women. Incidence of oesophageal SCC is also 
high in southern and eastern Africa.9–11 The prevalence of 
oesophageal adenocarcinoma is increasing in some 
Asian countries, such as Singapore. In the USA, 
16 470 cases of oesophageal carcinoma were newly 
diagnosed in 2009, and 14 530 deaths were expected to 
occur in the same year.2 From 1975 to 2004, age-adjusted 
incidence of oesophageal carcinoma in white men 
increased from 5·76 to 8·34 per 100 000 person-years, 
largely due to to 463% increase in oesophageal adeno-
carcinoma. In white women an increase, albeit less 
striking, was also seen in oesophageal adenocarcinoma.12 
In African American men, SCC is the predominant type 
of oesophageal carcinoma.11 The rising incidence of 
oesophageal adenocarcinoma in the USA is not due to 
either overdiagnosis or reclassiﬁ cation of disease on the 
basis of histology or location.5 In the UK, the incidence of 
oesophageal adenocarcinoma has increased sharply. 
In a National Cancer Registry study of more than 
40 000 patients, Lepage and colleagues4 reported a rise in 
incidence across all socioeconomic categories in England 
and Wales between 1971 and 2001 (appendix p 2). The 
age-adjusted incidence has risen by 39·6% for men and 
37·5% for women every 5 years. A similar trend has been 
noted in other countries in western Europe, such as 
France, Finland, and the Netherlands.11,13 Similarly, in 
Australia an annual increase in incidence of more than 
4·2% was seen.14
Pathophysiology and pathogenesis
Squamous-cell carcinoma
Risk factors for SCC are shown in the panel.15–21 Tobacco 
use has been associated with increased risk of oesopha-
geal SCC and adenocarcinoma related to nitrosamine 
exposure.22–24 Alcohol consumption is a risk factor for 
oesophageal SCC but not for adenocarcinoma.24,25 The 
pathophysiology in SCC probably involves the alcohol 
metabolite aldehyde, which is a recognised carcinogen. 
Mutations in enzymes that metabolise alcohol have been 
associated with increased risk of SCC.15 The combination 
of tobacco and alcohol consumption further increases 
the risk of SCC (panel).25 Other important factors are low 
Search strategy and selection criteria
We searched PubMed to identify papers that addressed the epidemiology, pathogenesis, 
prevention, selection of patients, staging strategies, surgical treatments, extent of resection, 
and the role of multimodal therapies for oesophageal cancer, published in any language 
from 1980 to 2010. We used the following search terms: “esophageal cancer”, 
“epidemiology”, “pathophysiology”, “prevention”, “esophagectomy”, “staging”, “mortality”, 
“surgical approach”, “endoscopic therapy”, “chemotherapy”, “radiation therapy”, 
“chemoradiation”, “multimodality therapy”, “neoadjuvant therapy”, and “adjuvant therapy”. 
We manually searched the reference lists of selected articles for additional articles. 
Additionally, we did focused searches for systematic reviews, Cochrane reviews, and 
meta-analyses, published from 2005 to 2010, in Embase and Cochrane Library. A few 
selected references from 2011 and 2012 were added during the article revision process.
See Online for appendix
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socioeconomic status, poor oral hygiene, and nutritional 
deﬁ ciencies.3,17–20
Oesophageal adenocarcinoma
The major risk factors for oesophageal adenocarcinoma 
are summarised in the panel. They include symptomatic 
gastro-oesophageal reﬂ ux disease (GORD), obesity, 
Barrett’s oesophagus, tobacco use, and a diet that is low 
in vegetables and fruit.26–32 Risk might be decreased in 
patients with a history of Helicobacter pylori infection.29
Symptomatic GORD is one of the strongest risk factors 
for oesophageal adenocarcinoma, although symptoms are 
infrequent or absent in more than 40% of patients.31 
Obesity, which is increasing worldwide, is also an 
important risk factor for oesophageal adeno carcinoma and 
is associated with GORD; these disorders might interact to 
increase further the risk of oesophageal adenocarcinoma.33–36
In Barrett’s oesophagus the squamous mucosa is 
replaced by columnar epithelium, and upper-oesophageal 
endoscopy shows a cephalad displacement of slamon-
coloured mucosa into the oesophagus (appendix p 4). 
These changes are strongly associated with oesophageal 
adenocarcinoma.32,37,38 The presence of goblet cells in the 
columnar epithelium is a diagnostic criterion for 
Barrett’s oesophagus in the USA, but is not included in 
the British Society of Gastro enterology guideline 
(appendix p 7). The reported prevalence of Barrett’s 
oesophagus is 1·6% in the general population and 
10–15% in patients who undergo endo scopic assessment 
for reﬂ ux symptoms.39,40 GORD and bile reﬂ ux are risk 
factors for Barrett’s oesophagus.41,42 Reﬂ ux injures the 
normal squamous mucosa, and Barrett’s oesophagus is 
thought to be a protective adaption.43 Abdominal obesity 
might be a risk factor for Barrett’s oesophagus.44
The risk of oesophageal adenocarcinoma in patients 
with Barrett’s oesophagus has been estimated to be 
0·5% per year, but in one study was calculated to be as 
low as 0·12% per year (appendix p 7). The risk is highest 
in patients with high-grade dysplasia of the oesophagus,45 
which progresses to adenocarcinoma in 16–59% of 
patients.45–47 In a meta-analysis, the weighted incidence 
of oesophageal adenocarcinoma in patients with 
Barrett’s oesophagus and high-grade dysplasia was 
6·58 per 100 person-years.48 Genetic abnormalities in 
Barrett’s oesophagus (eg, chromosomal instability, cell-
cycle abnormalities, and TP53 and KI67 staining) are 
potential biomarkers for progression to oesophageal 
adenocarcinoma.26,49–51
Assessment
Clinical presentation
Dysphagia is the most common symptom of oesophageal 
carcinoma, although the number of asymptomatic patients 
in whom a diagnosis has been made by sur veillance 
endoscopy has increased.52,53 In patients with SCC, the 
most common presentation is dysphagia, typically 
accompanied by weight loss and a history of smoking and 
alcohol intake.54 By contrast, most patients with adeno-
carcinoma are white men with a history of GORD who 
have recently developed dysphagia. Weight loss is not a 
frequent ﬁ nding. Endoscopy typically shows a tumour in 
the distal oesophagus or gastro-oesophageal junction.
Diagnosis
Barium oesophagography is widely used as the initial 
assessment in patients who present with symptoms of 
oesophageal carcinoma.55 However, oesophagogastro-
duodenoscopy is required to obtain biopsy samples to 
conﬁ rm the diagnosis of oesophageal carcinoma and, 
therefore, is preferentially used ﬁ rst in many patients. 
This approach also enables physicians to assess whether 
the cardia and stomach are involved in patients with 
adenocarcinoma of the distal oesophagus, and to see the 
proximal extent of the tumour and its relation to the 
cricopharyngeus in patients with SCC. In patients with 
severe stricture, careful dilatation might be required to 
assess the extent of the tumour. Bronchoscopy is 
recommended for mid-oesophageal tumours to ex clude 
airway involvement. Biopsy of abnormalities in the 
oesophageal wall guided by endoscopic ultrasonography 
might also lead to diagnosis.56
Staging
Once a diagnosis of oesophageal carcinoma is made, 
accurate staging must be done before treatment to 
ensure that the correct protocols are applied and that 
Panel: Risk factors for oesophageal cancer
Oesophageal SCC
• Tobacco use
• Alcohol consumption
• Mutations of enzymes that metabolise alcohol
• Achalasia
• Caustic injury
• History of thoracic radiation
• Low socioeconomic status
• Poor oral hygiene
• Nutritional deﬁ ciencies
• Non-epidermolytic palmoplantar keratoderma
Oesophageal adenocarcinoma
• Symptomatic gastro-oesophageal reﬂ ux disease
• Barrett’s oesophagus
• Obesity
• Tobacco use
• History of thoracic radiation
• Diet low in vegetables and fruits
• Increased age
• Male sex
• Medications that relax the lower oesophageal sphincter
• Familial history (rare)
SCC=squamous-cell carcinoma.
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results can be adequately assessed.7,57 The TNM (tumour, 
node, metastasis) staging system takes into account the 
depth of tumour invasion, the nodal status, and the 
presence or absence of metastatic disease. The system 
has changed over time, and the version used in studies 
must be known to compare data. The current staging 
system is shown in table 1. Notable changes in the latest 
version are the classiﬁ cation of T4 lesions as resectable 
(T4a) or unresectable (T4b), and stratiﬁ cation of N status 
on the basis of number of nodes involved (ﬁ gure). M1 
now refers to distant metastases, and the classiﬁ cations 
M1a and M1b are no longer in use. Other changes include 
stratiﬁ cation of stage according to histology, degree of 
diﬀ erentiation, and the location of the tumour.59
The staging work-up should involve various 
approaches, including history, physical examin ation, 
upper-gastrointestinal endoscopy, CT of the chest and 
abdomen (useful to assess local spread of disease and 
metastases), PET, endoscopic ultrasonography, and 
bronchoscopy (for midoesophageal or upper-oesophageal 
lesions).54 Minimally invasive staging is also used select-
ively in some institutions (appendix p 7).57 Molecular 
staging with analysis of gene expression proﬁ les and to 
detect micrometastases in lymph nodes is currently 
under investigation.60,61 The most important techniques 
are endoscopic ultrasonography, PET, CT, and, at some 
institutions, minimally invasive staging.
Endoscopic ultrasonography
Endoscopic ultrasonography provides detailed informa-
tion on the oesophageal wall and is important in the 
assessment of tumour status (T descriptor). The accuracy 
of tumour staging by this method varies according to the 
stage and ranges from 73% to 89%.62 Endoscopic ultra-
sonography can be used to assess nodal status in node-
positive patients with an accuracy of up to 84%, but 
accuracy falls to around 69% when patients with N0 
status are taken into account.54,62 The obtaining of biopsy 
samples by ﬁ ne-needle aspiration during endoscopic 
ultrasonography can improve the accuracy of nodal 
staging, although the endoscope might be unable to 
advance through tight strictures and cannot traverse the 
tumour to sample the node. In a study of endoscopic 
ﬁ ne-needle aspiration, accuracy was 72% for overall 
staging and 90% for nodal staging.63
PET
¹⁸F-ﬂ uorodeoxyglucose PET (FDG-PET) is increasingly 
being used to stage oesophageal cancer, but it is not 
useful to establish tumour status (T descriptor), and 
accuracy in the assessment of nodal status varies widely 
(27–90%).54 The primary usefulness of FDG-PET is the 
detection of distant metastatic disease.64 Promising 
ﬁ ndings have also been reported for the assessment of 
response to induction chemotherapy. In a prospective 
study, PET was used to assess response early after 
neoadjuvant chemotherapy.65 Patients who responded 
early com pleted chemotherapy treatment before they 
underwent oesophagectomy, whereas non-responders 
underwent surgery immediately. Survival diﬀ ered 
signiﬁ cantly between patients who responded to 
treatment and those who did not (median event-free 
survival 29·7 months [95% CI 23·6–35·7] vs 14·1 months 
[7·5–20·6]; hazard ratio 2·18 [1·32–3·62], p=0·002). 
FDG-PET might be less accurate in the early assessment 
of response to induction chemoradiation than to 
neoadjuvant chemotherapy (appendix p 7).
Minimally invasive staging
Minimally invasive staging with laparoscopy or thoraco-
scopy is not widely practised, but can be very useful in 
selected patients.7,57 We have reported better accuracy 
with minimally invasive staging than with PET in the 
diagnosis of distant metastases, especially for lesions 
Tumour 
status
Nodal 
status
Metastatic 
status
Grade Tumour 
location
Squamous-cell carcinoma
0 Tis (HGD) N0 M0 1, X Any
IA T1 N0 M0 1, X Any
IB T1
T2–3
N0
N0
M0
M0
2–3
1, X
Any
Lower, X
IIA T2–3
T2–3
N0
N0
M0
M0
1, X
2–3
Upper, middle
Lower, X
IIB T2–3
T1–2
NO
N1
M0
M0
2–3
Any
Upper, middle
Any
IIIA T1–2
T3
T4a
N2
N1
N0
M0
M0
M0
Any
Any
Any
Any
Any
Any
IIIB T3 N2 M0 Any Any
IIIC T4a
T4b
Any
N1–2
Any
N3
M0
M0
M0
Any
Any
Any
Any
Any
Any
IV Any Any M1 Any Any
Adenocarcinoma
0 Tis (HGD) N0 M0 1, X NA
IA T1 N0 M0 1–2, X NA
IB T1
T2
N0
N0
M0
M0
3
1–2, X
NA
NA
IIA T2 N0 M0 3 NA
IIB T3
T1–2
N0
N1
M0
M0
Any
Any
NA
NA
IIIA T1–2
T3
T4a
N2
N1
N0
M0
M0
M0
Any
Any
Any
NA
NA
NA
IIIB T3 N2 M0 Any NA
IIIC T4a
T4b
Any
N1–2
Any
N3
M0
M0
M0
Any
Any
Any
NA
NA
NA
IV Any Any M1 Any NA
Tis=intraepithelial neoplasia. HGD=high-grade dysplasia. NA=not applicable. 
Reproduced from reference 58 by permission of American Joint Cancer 
Committee on Cancer.
Table 1: Stage classiﬁ cation for oesophageal carcinoma in the 2010 TNM 
staging system
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with diameter smaller than 1 cm (appendix p 5),66 and 
than with endoscopic ultrasonography for the diagnosis 
of lymph-node metastasis.67 Minimally invasive staging, 
however, has potential disadvantages: general anaes-
thesia is required and the procedure is expensive. Since 
minimally invasive staging with laparoscopy is par-
ticularly useful in the detection of occult distant 
metastases and the exclusion of patients from deﬁ nitive 
surgical resection, it can be used before laparotomy, at 
the time of planned resection.
Treatment of oesophageal carcinoma
Locally advanced disease, deﬁ ned by the extent of the 
primary tumour and involvement of locoregional lymph 
nodes (higher than stage T2, node positive without 
distant metastases, or both), is generally treated with 
curative intent with a multimodal approach that 
includes surgery. Advanced (metastatic or disseminated) 
and recurrent disease are treated with palliative intent 
with chemotherapy to extend survival and local 
therapies, such as radiotherapy, or endoscopic therapies, 
such as stents, to treat dysphagia. Tumour histology and 
location aﬀ ect the choice of chemo therapeutics and 
approach to surgery, but are seldom used as stratiﬁ cation 
factors for treatment. Generally, the surgical members 
of the multidisciplinary team determine resectability for 
patients with locally advanced oesophageal carcinoma, 
after which the speciﬁ cs of neoadjuvant treatment, 
timing of surgery, and adjuvant therapies are discussed. 
Non-surgical palliative measures for patients with 
tumours that are deemed inoperable because of 
coexisting comorbidities or advanced cancer are decided 
by the multi discipli n ary team.
Surgical treatment
Resection
Surgical options for resection of oesophageal carcinoma 
include transhiatal oesophagectomy and transthoracic 
approaches, such as Ivor Lewis oesophagectomy (abdom-
inal and right thoracic approach; also called Lewis-
Tanner oesophagectomy), the three-incision modiﬁ ed 
McKeown oesophagectomy that involves laparot omy, 
right thora cotomy, and neck anastomosis, and left 
thoracotomy or a left thoracoabdominal approach.7,68–74 
The choice of surgical approach depends on the location 
of the tumour and the preference of the surgeon. All the 
procedures are complex and, therefore, treatment in 
high-volume centres with experienced surgeons and the 
availability of critical-care support is associated with 
improved outcomes.75,76
Meta-analyses and randomised trials that have assessed 
open oesophagectomy have shown no signiﬁ cant diﬀ er-
ences in long-term survival between techniques.77–80 In one 
large randomised study that compared trans thoracic 
oesophagectomy and transhiatal oesoph agectomy, mor-
tality was similar in the two groups, although morbid-
ity was decreased with transhiatal oesophagectomy. 
Non-signiﬁ cant associations with disease-free and overall 
survival were seen in the trans thoracic oesophagectomy 
group. A subgroup analysis of patients without exten-
sive nodal involvement revealed improved locoregional 
disease-free survival with a transthoracic approach.81
Lymph-node dissection
The extent of lymph-node dissection required in patients 
with oesophageal carcinoma is controversial. Proponents 
of transhiatal oesophagectomy typically dissect the 
abdominal lymph nodes and limit dissection of thoracic 
lymph nodes. Three-ﬁ eld lymphadenectomy in the 
abdomen, chest, and neck (with dissection of nodes 
along the recurrent nerves) is mainly practised in Japan 
where SCC predominates.82 In Europe and the USA, this 
approach has few proponents71,83 and two-ﬁ eld lympha-
denectomy in the abdomen and chest is more commonly 
used. In a randomised study of two-ﬁ eld versus three-
ﬁ eld lymphadenectomy, the complication rate was 
signiﬁ cantly higher with three-ﬁ eld lymph adenectomy 
and no signiﬁ cant diﬀ erences were seen in recurrence or 
survival.82 The survival advantage with three-ﬁ eld 
dissection reported in some non-randomised trials might 
be attributable at least partly to stage migration due to 
improved staging rather than any therapeutic beneﬁ t of 
the dissection itself.83 The need for adequate lymph-node 
sampling to ensure accurate staging is, however, 
becoming evident.84
Minimally invasive oesophagectomy
The risks associated with oesophagectomy, including 
mortality of 1–23%, are of concern.75 In an eﬀ ort to 
Figure: Features used to stage oesophageal carcinoma according to the latest version of the TNM 
classiﬁ cation system 
Notable updates are the classiﬁ cation of T4 lesions as resectable (T4a) or unresectable (T4b), and the 
stratiﬁ cation of N status on the basis of number of nodes involved. Tis=intraepithelial neoplasia. 
HGD=high-grade dysplasia. Reproduced by permission of Cleveland Clinic Center for Medical Art and 
Photography, Cleveland, OH, USA.
N1
N2
N3 
1 or 2
3–6
≥7
NO
M1
Pleura
Perioesophageal
tissue
Epithelium
T2
T3 T4a T4b
Basement membrane
Lamina propria
Muscularis mucosae
Submucosa
Muscularis propria
Aorta
T1Tis (HGD)
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decrease the morbidity and mortality of open oesophag-
ectomy, we and others have adopted minimally invasive 
approaches (appendix p 6). In a large series of 
1011 consecutive minimally invasive oesophagectomies 
done with a combined laparoscopic and thoracoscopic 
approach, the median stay in intensive care after surgery 
was 2 days (IQR 1–3), and in hospital was 8 days (6–14), 
and the 30-day operative mortality was 1·7%.85 The 
oncological results per stage were similar to those of 
historical series of open oesophagectomy.
The preliminary results of the Eastern Cooperative 
Oncology Group (ECOG), phase 2, prospective, multi-
institutional study (ECOG 2202) of minimally invasive 
oesophagectomy showed low mortality (2%).86 The 
estimated 3-year overall survival was 50% and stage-
speciﬁ c survival was similar to that in open series. Longer 
follow-up is required to fully assess the onco logical 
outcomes of minimally invasive oesophagectomy.
A randomised trial of minimally invasive oesopha-
gectomy compared with open oesophagectomy showed a 
decrease in the frequency of pulmonary complications in 
the minimally invasive group.87 Retrospective comparison 
has shown improvements in perioperative morbidity 
with minimally invasive oesophagectomy.7,68,88 In a 
systematic review of studies that in total involved more 
than 1100 patients, minimally invasive oesophagectomy 
was associated with decreased morbidity compared with 
open esophagectomy,89 although all the studies assessed 
were retrospective. This study design has inherent 
limitations and selection bias, and the results should be 
interpreted with caution.
Quality of life after oesophagectomy is an important 
consideration.68 An early study showed that quality-of-life 
scores after oesophagectomy initially worsened, with 
reduced scores being reported at 6 weeks, but had 
returned to baseline values by 9 months in patients who 
survived longer than 2 years (appendix p 7). In another 
study, quality of life declined after surgery, but was 
restored within 1 year (appendix p 7). Minimally invasive 
oesophagectomy seems to preserve quality of life 
(appendix p 7).
Neoadjuvant chemotherapy with surgical resection
The combination of chemotherapy with surgery can be 
used to control the early spread of systemic disease.90 
Large, randomised trials of chemotherapy before and after 
surgery in patients with oesophageal SCC or adeno-
carcinoma have shown conﬂ icting results (table 2). In a 
US study of patients randomly assigned to neoadjuvant 
chemotherapy followed by surgery or surgery alone, 3-year 
overall survival did not diﬀ er between groups.91 By 
contrast, one of the largest randomised studies to date, the 
UK Medical Research Council Oesophageal Cancer 
Working Group study, found that the use of chemo therapy 
before surgery signiﬁ cantly improved 3-year survival 
compared with surgery alone (appendix p 7).92 On the 
basis of these results, neoadjuvant chemotherapy followed 
by resection has become a common approach in the UK 
for locally advanced disease. In the MAGIC trial,93 
chemotherapy given before and after surgery signiﬁ cantly 
improved 5-year overall survival compared with surgery 
alone. Whether these results are gen eralisable to all 
oesophageal adenocarcinoma, how ever, is unclear because 
gastro-oesophageal-junction tumours and oesophageal 
adenocarcinoma accounted for only 26% of the tumours 
in the trial.
Neoadjuvant chemoradiotherapy and surgery
In the USA, neoadjuvant chemoradiotherapy is com-
monly used for locally advanced oesophageal carcinoma. 
Many randomised trials have assessed chemo radio -
therapy followed by surgery compared with sur gery 
alone in patients with potentially resectable oesophageal 
carcinoma (table 3).94–100 Most studies have shown non-
signiﬁ cant results. Two showed signiﬁ cant survival 
beneﬁ t with concurrent chemoradiotherapy.98,99 One of 
these studies, however, had several notable limitations, 
including short follow-up, the absence of CT staging 
(which could have led to imbalances between the 
treatment groups), and 3-year survival with surgery 
alone of 6%,98 which is lower than expected.90 The other 
study closed prematurely because of poor accrual.99 
Survival seemed to favour the chemo radiotherapy group, 
Number of 
patients
Study treatments Chemotherapy regimen Histology Median 
survival 
(months)
Overall survival (%)
Kelsen et al, 199891 440 Surgery vs surgery 
and chemotherapy
Cisplatin+ﬂ uorouracil for 
three cycles before surgery
204 (46%) SCC, 236 (54%) 
adenocarinoma
14·9 vs 16·1 (3-year) 26% vs 23%
MRC, 200292
and Allum et al, 2009*
802 Surgery vs surgery 
and chemotherapy
Cisplatin+ﬂ uorouracil for 
two cycles before surgery
247 (31%) SCC, 533 (66%) 
adenocarcinoma, 24 (3%) 
undiﬀ erentiated or unknown
13·3 vs 16·8 (5-year) 17% vs 23%†
Cunningham et al, 
200693
503 Surgery vs surgery 
and chemotherapy
Epirubicin+cisplatin+ 
ﬂ uorouracil for three cycles 
before and after surgery
503 (100%) adenocarcinoma
(372 [74%] gastric,
131 [26%] oesophageal)
NR (5-year) 23% vs 36%†
SCC=squamous-cell carcinoma. MRC=Medical Research Council Oesophageal Cancer Working Group. NR=not reported. *Appendix p 7. †Signiﬁ cant diﬀ erence in favour of the 
neoadjuvant chemotherapy group. 
Table 2: Results of randomised trials of neoadjuvant chemotherapy
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but this ﬁ nding must be interpreted with caution. A 
multicentre study reported in 2012 (CROSS), showed a 
beneﬁ t with chemo radiotherapy, particularly in patients 
with SCC (appendix p 7). A meta-analysis has also shown 
a beneﬁ t for neoadjuvant chemo radiotherapy.101 Studies 
have started to assess pre operative chemora diotherapy 
that uses next-generation platinums, such as oxaliplatin, 
and bio logically targeted agents.102
Surgery with adjuvant chemotherapy, radiation, 
or chemoradiation
Adjuvant chemotherapy for oesophageal carcinoma 
treated with primary resection might be beneﬁ cial, 
especially in patients with node-positive disease (table 4, 
appendix pp 7–8).7,103–106 In a phase 2 trial (ECOG E8296) 
of adjuvant cisplatin and paclitaxel in patients with 
completely resected oesophageal adenocarcinoma, 
49 (89%) of 55 patients had node-positive disease.103 
Despite N1 disease, 2-year survival was 60%, which 
compares well with the ﬁ ndings of other studies of 
neoadjuvant chemotherapy (table 2) and suggests that 
this approach is beneﬁ cial in oesophageal adeno-
carcinoma. Several randomised trials by the Japan 
Clinical Oncology Group assessed surgery with or 
without chemotherapy in patients with SCC.104,105 In one 
study of adjuvant chemotherapy, 5-year disease-free 
survival favoured the combined therapy group.105 In a 
randomised study of observation alone or adjuvant 
chemoradiotherapy after resection, survival was signiﬁ -
cantly better with adjuvant chemoradiotherapy.106
Number of 
patients
Study 
treatments
Regimen Histology Median 
survival 
(months)
Overall survival (%)
Le Prise et al, 199494 86 Surgery vs 
surgery and CRT
Sequential cisplatin+ﬂ uorouracil 
and RT to 20·0 Gy
86 (100%) SCC 10·0 vs 10·0 (1-year) 47% vs 47%
Walsh et al, 199698 103 Surgery vs 
surgery and CRT
Concurrent cisplatin+ﬂ uorouracil 
and RT to 40·0 Gy
103 (100%) adenocarcinoma 11·0 vs 16·0 (3-year) 6% vs 32%*
Bosset et al, 199795 282 Surgery vs 
surgery and CRT
Sequential interrupted cisplatin 
and RT to 37·0 Gy
282 (100%) SCC 18·6 vs 18·6 (3-year) 34% vs 36%
Urba et al, 200196 100 Surgery vs 
surgery and CRT
Concurrent cisplatin+ﬂ uorouracil 
+vinblastine and RT to 45·0 Gy
25 (25%) SCC,
75 (75%) adenocarcinoma 
17·6 vs 16·9 (3-year) 16% vs 30%
Burmeister et al, 
2005100
256 Surgery vs 
surgery and CRT
Concurrent cisplatin+ﬂ uorouracil 
and RT to 35·0 Gy
95 (37%) SCC,
158 (62%) adenocarcinoma,
3 (1%) mixed or other
22·2 vs 19·3 NR
Tepper et al, 200899 56 Surgery vs 
surgery and CRT
Concurrent cisplatin+ﬂ uorouracil 
and RT to 50·4 Gy
14 (25%) SCC,
42 (75%) adenocarcinoma
21·5 vs 53·8 (5-year) 16% vs 39%*
CRT=chemoradiotherapy. RT=radiotherapy. SCC=squamous-cell carcinoma. NR=not reported. *Signiﬁ cant diﬀ erence in favour of neoadjuvant chemoradiotherapy.
Table 3: Results of randomised trials of neoadjuvant chemoradiotherapy
Number of 
patients
Study treatments Regimen Histology Median 
survival 
(months)
Overall survival (%)
Macdonald et al, 
2001106
556 Surgery vs surgery and 
adjuvant CRT
Sequential and 
concurrent CRT 
with ﬂ uorouracil
556 (100%) adenocarcinoma 
(445 [80%] stomach, 111 [20%] 
gastro-oesophageal junction)
27 vs 36 (3-year) 41% vs 50%*
Ando et al, 2003105 242 Surgery vs surgery and 
adjuvant chemotherapy
Fluorouracil+ 
cisplatin
242 (100%) SCC NR (5-year) 52% vs 61%†
Armanios et al, 
2004103‡
55 Surgery and adjuvant 
chemotherapy
Cisplatin+ paclitaxel 55 (100%) adenocarcinoma 31·2 (3-year) 42%
Xiao et al, 2003§ 495 Surgery vs surgery and 
adjuvant RT
50·0–60·0 Gy in 
25–30 fractions
495 (100%) SCC NR (5-year) 31·7% vs 41·3%
Ténière et al, 1991§ 221 Surgery vs surgery and 
adjuvant RT
45·0–55·0 Gy 221 (100%) SCC 18 vs 18 (5-year) 17·6% vs 18·6%
Fok et al, 1993§ 130 Surgery vs surgery and 
adjuvant RT
49·0–52·5 Gy in 
14 fractions
104 (80%) SCC, 
26 (20%) adenocarcinoma
15·2 vs 
8·7¶
NR
Zieren et al, 1995§ 68 Surgery vs surgery and 
adjuvant RT
Up to 30·6 Gy 68 (100%) SCC NR (3-year) 20% vs 22%
CRT=chemoradiotherapy. RT=radiotherapy. SCC=squamous-cell carcinoma. NR=not reported. *Diﬀ erence signiﬁ cant for overall survival. †Although overall survival did not 
diﬀ er (p=0·13), disease-free surival was improved with adjuvant chemotherapy (45% vs 55%, p=0·037). ‡Phase 2 non-randomised, non-controlled trial. §Appendix pp 7–8. 
¶Diﬀ erence signiﬁ cant for median survival.
Table 4: Results of trials of adjuvant chemotherapy, radiotherapy, and chemoradiotherapy
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Randomised trials of adjuvant radiation without 
chemo therapy have not consistently shown beneﬁ ts 
(table 4), and its indication is for positive margins or 
residual tumour (appendix pp 7–8).
Neoadjuvant chemoradiation is commonly used in the 
USA for locally advanced oesophageal carcinoma, whereas 
in Europe neoadjuvant chemotherapy is a common 
approach.91–101 In patients with gastro-oesophageal-junction 
or gastric adenocar cinoma, adjuvant chemoradiotherapy 
after resection is an acceptable approach, but the ﬁ ndings 
of studies are not generalisable to all patients with 
oesophageal carcinoma.106 Adjuvant chemotherapy is 
typically used for node-positive disease in Asia, where 
SCC predominates, and also seems to show some beneﬁ t 
in oesophageal adenocarcinoma.103–105
Non-surgical treatment
Radiotherapy
Historically, external beam radiotherapy has played an 
important part in the management of unresectable 
oesophageal carcinoma. Although this approach alone 
can be a useful palliative treatment for dysphagia, 
sustained remission and long-term survival are rarely 
achieved. Chemoradiotherapy is the preferred approach 
for patients who are suitably ﬁ t for combined therapy 
because it provides better palliation than radiotherapy 
alone and improves the likelihood of long-term 
progression-free survival.107
Concurrent deﬁ nitive chemoradiation
The RTOG 85-01 trial,108,109 assessed radiotherapy versus 
chemoradiotherapy with cisplatin and ﬂ uorouracil, 
mainly in patients with SCC (90%). The estimated 5-year 
survival was 27% in the chemoradiotherapy group, but no 
5-year survival was seen in the radiotherapy group. This 
study, however, was done in the 1980s when staging did 
not require CT scanning, which might have led to 
imbalance between study groups. A follow-up trial 
(RTOG 94-05) compared chemoradiotherapy regimens 
with radiation doses of 64·8 Gy or 50·4 Gy (appendix p 8). 
The study was closed prematurely because of a lack of 
improved locoregional control and increased mortality in 
the high-dose radiotherapy group. On the basis of these 
results, 50·4 Gy is the standard dose used in the USA.
Although concurrent chemoradiotherapy without 
sur gery is accepted as a treatment for SCC, local control 
is signiﬁ cantly improved with surgery (appendix p 8).110 
In randomised trials of chemoradiotherapy followed by 
surgery versus chemoradiotherapy alone for SCC, local 
progression-free survival was signiﬁ cantly im proved in 
the surgery groups (appendix p 8),110 and surgery has 
been associated with improvement in dysphagia 
(appendix p 8).
Salvage oesophagectomy after deﬁ nitive chemoradiation
The rate of locoregional recurrence after deﬁ nitive 
chemoradiation is high (40–60%, appendix p 8), and 
some patients are referred for salvage oesophagectomy. 
Typically, patients have received high-dose radiation and 
are referred for surgery several months after undergoing 
chemoradiotherapy. The morbidity and mortality of 
salvage oesophagectomy is higher than that of oesopha-
gectomy done in the neoadjuvant setting (appendix p 8). 
Despite the increase in perioperative risks, estimated 
5-year survival of 25% has been reported in selected 
patients (appendix p 8). Salvage oesophagectomy should 
be considered for highly selected patients in specialised 
centres (appendix p 8) and is not a routine option in all 
patients who do not respond to deﬁ nitive chemoradio-
therapy. Due consideration should therefore be given to 
planned oesophagectomy with neoadjuvant or adjuvant 
therapy, which has a lower morbidity.
Advanced, metastatic, or recurrent disease
Many patients with oesophageal carcinoma have metas-
tases at diagnosis,8 and in these patients the goal is to 
prolong and maximise quality of life. Chemotherapy or 
chemoradiation is eﬀ ective in around 50% of patients, 
but management of pain and nutrition is eﬀ ective in 
almost all. Pain is treated with combined short-acting 
and long-acting narcotics and local radiotherapy (eg, for 
bone metas tases). Dysphagia may be improved with 
endoscopic therapies or brachytherapy (appendix p 9).
Palliative chemotherapy is chosen on the basis of 
projected eﬃ  cacy, the patient’s performance status and 
comorbidities and on the side-eﬀ ect proﬁ les of relevant 
agents.111–118 Few regimens have been validated in phase 3 
trials. Combinations of cisplatin and ﬂ uorouracil are 
better than the best supportive care, particularly for 
SCC.111 Regimens for oesophageal adenocarcinoma now 
frequently use three drugs and some incorporate bio-
logical or targeted therapies. A widely used regimen for 
patients with advanced gastro-oesophageal carcinoma is 
irinotecan and cisplatin.112–114 Van Cutsem and col leagues115 
did a randomised trial of cisplatin and ﬂ uoro uracil versus 
docetaxel plus cisplatin and ﬂ uorouracil in 445 patients 
with advanced gastro-oesophageal-junction and gastric 
cancers. The addition of docetaxel signiﬁ cantly length-
ened the time to progression and overall survival.
The REAL-2 study of 1002 patients with oesoph-
agogastric cancers assessed three-drug regimens that 
included epirubicin plus oxaliplatin or cisplatin and 
ﬂ uorouracil or capecitabine.116 The primary outcome of 
non-inferiority in overall survival was reached and 
favoured better survival in the group that received 
epirubicin, oxaliplatin, and capecitabine (table 5). Studies 
of metastatic disease, however, have mainly involved 
gastric cancers, and the results are not generalisable to 
all oesophageal carcinoma. The preliminary results of 
the REAL-3 trial of epirubicin, oxaliplatin, and 
capecitabine with or without panitumumab in patients 
with advanced oesopha go gastric cancer have been 
reported and suggest decreased survival in the 
panitumumab group (appendix p 9).
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Biological and targeted therapies
Agents containing small molecules and antibodies that 
have been created on the basis of tumour biology are 
being incorporated into multimodal therapies.118 The 
most commonly used agents include the angiogenesis 
inhibitor bevacizumab and the inhibitors of epidermal-
growth-factor receptors, panitumumab, cetuximab, 
and erlotinib. Further studies are underway to assess 
these drugs.
Endoscopic treatment
Although endoscopic therapies are widely used to treat 
advanced or inoperable cancers, they have gained 
interest as potential curative approaches for early-stage 
oesoph ageal carcinoma. Barrett’s oesophagus and early-
stage cancer might be treatable endoscopically with 
resection or ablation. Resection techniques have the 
advantage of enabling sample collection for histological 
assessment and T-staging, and include mucosal 
resection and submucosal dissection for large lesions. 
Endoscopic ablation therapies include photodynamic 
therapy, argon plasma coagulation, and radiofrequency 
ablation, which enable treatment of large areas but 
cannot be used to collect samples.119,120 In Europe and 
Japan, endoscopic resection is used mainly, and endo-
scopic ablation is used as an adjunct. In the USA, 
ablative therapy is the ﬁ rst-line approach with resection 
as an adjunctive approach.
Staging (TNM) must be conﬁ rmed before endoscopic 
therapy is started. Depth of invasion and other tumour 
characteristics, such as length, diﬀ erentiation, and 
angiolymphatic invasion, should be assessed in addition 
to nodal (N) and metastatic (M) status. Ell and colleagues121 
used endoscopic mucosal resection and photodynamic 
therapy to treat 100 highly selected patients who had T1 
intramucosal cancer and reported an estimated 3-year 
survival of 98%. These results are encouraging, but the 
resection margins were positive in around a third of 
patients, and recurrent or metach ronous lesions were 
detected in 11% of patients during a median follow-up of 
33 months. In a study of resection of T1 tumours, 
multifocal neoplasia, angiolymphatic invasion, or nodal 
metastases were frequently noted irrespective of tumour 
depth, which led the authors to conclude that endoscopic 
therapies should be reserved for high-risk patients.122 In 
our experience, the risk of N1 disease in patients with T1 
intramucosal lesions is 7%.6 Further work is required to 
deﬁ ne the role of endoscopic therapies with curative 
intent for oesophageal car cinoma.6,122,123
Endoscopic palliative treatments for dysphagia in pa-
tients with oesophageal carcinoma include oesophageal 
dilatation, esophageal stents, photodynamic therapy, 
neodymium-doped yttrium aluminium garnet (Nd:YAG) 
laser therapy, and brachytherapy.124 Self-expanding metal 
stents are the most commonly used oesophageal 
stents.125 In a randomised trial, brachytherapy was 
compared with stenting. Stenting provided earlier 
palliation of dys phagia, but the eﬀ ects of brachytherapy 
lasted longer with fewer complications (appendix p 8). 
Photodynamic therapy is used to treat obstructive 
endoluminal tumours and bleeding.126 Complications 
after this treatment include stricture and sunburn. In a 
Number of 
patients
Histology Regimen Outcomes
van Cutsem 
et al, 2006115*
221 198 (89·6%) adenocarcinoma
(42 [21·2%] gastro-oesophageal junction,
156 [78·8%] gastric, 21 [9·5%)] linitis 
plastica, 2 [0·9%] other)
Docetaxel 75 mg/m² plus cisplatin 75 mg/m² on day 1, 
followed by ﬂ uorouracil 750 mg/m² daily by 
continuous intravenous infusion for 5 days, repeated 
every 3 weeks
Response rate 37%, median 
survival 9·2 months
van Meerten 
et al, 2007117
51 4 (8%) SCC, 45 (88%) adenocarcinoma,
2 (4%) undiﬀ erentiated
Oxaliplatin 130 mg/m² on day 1 and capecitabine 
1000 mg/m² twice daily on days 1–14, repeated every 
3 weeks
Response rate 39%, median 
survival 8 months
Lee et al, 
2008†
45 45 (100%) SCC Cisplatin 60 mg/m² on day 1 and capecitabine 
1250 mg/m² per dose, twice daily on days 1–14
Response rate 58%, median 
survival 11·2 months
Cunningham 
et al, 2008116*
239 29 (12·1%) SCC, 209 (87·4%) 
adenocarcinoma, 1 (0·5%) undiﬀ erentiated
Epirubicin 50 mg/m² on day 1, oxaliplatin 130 mg/m² 
on day 1, and capecitabine 625 mg/m² twice daily on 
days 1–21, repeated every 3 weeks
Response rate 48%, median 
survival, 11·2 months
Bang et al, 
2009*†
294 294 (100%) adenocarcinoma‡
(58 [20%] gastro-oesophageal junction,
236 [80%] gastric)
800 mg/m² ﬂ uorouracil daily by IV infusion on days 1–5, 
or 1000 mg/m² capecitabine twice daily on days 1–14, 
plus 80 mg/m² cisplatin on day 1 by IV infusion, 
repeated every 3 weeks, and 8 mg/kg trastuzumab by 
IV infusion on day 1 of ﬁ rst cycle followed by 6 mg/kg 
every 3 weeks until disease progression
Response rate 47%, median 
survival 13·8 months
Ajani et al, 
2010*†
521 521 (100%) adenocarcinoma
(82 [15·7%] gastro-oesophageal junction,
438 [84·1%] gastric, 1 [0·2%] both)
Cisplatin 75 mg/m² on day 1 and S-1 (ﬂ uoropyrimidine) 
50 mg/m² divided across twice daily doses on days 
1–21, repeated every 28 days
Response rate 29%, median 
survival 8·6 months
SCC=squamous-cell carcinoma. IV=intravenous. *Results given for treatment with the best survival outcome in a comparison of two or more treatments. †Appendix pp 8–9. 
‡Restricted to patients with HER2 (also known as ERBB2)-positive tumours.
Table 5: Studies of ﬁ rst-line chemotherapy for metastatic oesophageal cancer
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randomised, multicentre trial of photodynamic therapy 
compared with Nd:YAG laser therapy in patients with 
obstructive oesophageal carci noma, both approaches 
provided equal relief of dysphagia, but the objective 
tumour response was better and acute perforations 
were fewer in the photodynamic-therapy group.127 
Locally advanced oesophageal carcinoma can also cause 
tracheo-oesophageal ﬁ stulas, which are typically treated 
with a covered oesophageal stent.
Prevention, surveillance, and screening
Although several potential preventive measures exist, 
none has been proven to decrease the risk of oesophageal 
carcinoma in prospective well-designed trials.26,27
Chemoprevention
Various nutrients and minerals have been tested for 
preventive eﬀ ects against oesophageal carcinoma, in-
cluding retinol, riboﬂ avin, zinc, selenium, β-carotene, 
and α-tocopherol; none has yet shown notable preventive 
eﬀ ects in randomised trials.128,129 Chemoprevention trials 
of black raspberries, which have a high concentration of 
a nitrosamine inhibitor,130 and of selenium are in 
progress.131 Chemopreventive actions have been sug-
gested for non-steroidal anti-inﬂ ammatory drugs and 
inhibitors of cyclo-oxygenase 2,132 although a randomised 
trial of the latter in Barrett’s oesophagus showed no 
signiﬁ cant beneﬁ t.133 Aspirin has shown a protective 
eﬀ ect in population-based studies. A randomised 
chemo prevention trial, AspECT, is underway in the UK 
to assess aspirin plus twice-daily esomeprazole versus 
esomepra zole alone in patients with Barrett’s 
oesophagus but without high-grade dysplasia.134
Other suggested but as yet unproven measures to 
lower the incidence of oesophageal carcinoma include 
cessation of smoking and alcohol consumption, lifestyle 
modiﬁ cations to increase exercise and reduce weight, 
and the inclusion of substantial intake of fruit and 
vegetables in the diet.
Screening for Barrett’s oesophagus
Whether endoscopic screening programmes to detect 
Barrett’s oesophagus in patients with chronic GORD 
symptoms are useful has been debated. Critics point out 
the high number of people in the general population 
who have reﬂ ux symptoms and the fact that at least 40% 
of patients with Barrett’s oesophagus do not have reﬂ ux 
symptoms, and question the cost-eﬀ ectiveness of 
screening (appendix p 9). Proponents of screening for 
Barrett’s oesophagus point to the clear associations 
between reﬂ ux, Barrett’s oesophagus, and oesophageal 
adenocarcinoma, and suggest that the rising incidence of 
oesophageal adenocarcinoma jus tiﬁ es screening. No 
deﬁ nitive data are available on whether endoscopic 
screening for Barrett’s oesophagus is associated with a 
reduction in cancer-related mortality and, therefore, 
screening is not routinely recom mended.38,135
Prevention in patients with Barrett’s oesophagus
The major societies in North America and Europe support 
surveillance programmes after a diagnosis of Barrett’s 
oesophagus is made,136,137 and a randomised trial is 
underway to test the usefulness of endoscopic surveil-
lance.138 Neither acid suppression with medical therapy 
nor antireﬂ ux surgery prevents progression of Barrett’s 
oesophagus to cancer.139,140 Whether endo scopic therapies 
are useful for patients with Barrett’s oesophagus without 
dysplasia is controversial, and the consensus is to follow 
up patients with endoscopic surveillance and systematic 
biopsy.141 Advances in narrow-band imaging and confocal 
laser microendoscopy might facilitate diagnosis and 
directed biopsy.37,38,142
In patients with high-grade dysplasia, the options for 
preventive approaches include surveillance, endoscopic 
therapies, and surgical resection, but the optimum 
approach is debated. In an analysis of more than 
15 studies, the mean incidence of occult adenocarcinoma 
in patients with a preoperative diagnosis of high-grade 
dysplasia treated with oesophagectomy was 41%.45 
This high incidence provides a rationale for use of 
oesophagectomy, but there is concern about the risk of 
morbidity. Use of endoscopic treatments for high-grade 
dysplasia has been supported in two randomised trials. In 
one trial of photodynamic therapy plus proton-pump 
inhibitors compared with proton-pump inhibitors alone, 
progression to cancer was signiﬁ cantly decreased in the 
photodynamic-therapy group (13% vs 28%).119 In the other, 
which assessed endoscopic radiofrequency ablation in 
patients with Barrett’s oesophagus and high-grade 
dysplasia, radiofrequency ablation was more eﬀ ective in 
eradication of high-grade dysplasia than a proton-pump 
inhibitor alone, and the progression to cancer was lower 
(4% vs 22%) during short-term follow-up.120
Conclusions and future directions
The incidence of oesophageal carcinoma is increasing 
and substantial work is required to understand the 
causes of this rapid increase and the shift in epi-
demiology towards adenocarcinoma in some countries. 
Treatment of oesophageal carcinoma remains chal-
lenging but is best approached by a multidisciplinary 
team. Reﬁ nement of staging techniques, including 
molecular staging, is needed to understand prognosis 
and to tailor therapy to individuals to achieve the best 
possible outcomes. Technological advances in minimally 
invasive surgery, endoscopic treatments, and targeted 
agents, are being investigated and will hopefully also 
improve outcomes.
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